Idorsia Ltd News - 0RQE

Idorsia announces financial results for the first half 2024

Idorsia announces financial results for the first half 2024 Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024...

Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call

Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call Idorsia will publish its Half Year 2024 Financial...

Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension

Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension Idorsia receives approval...

Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds

Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds...

Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds

Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds Ad hoc announcement pursuant to Art. 53...

Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category

Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’...

Idorsia holds its Annual General Meeting of Shareholders

Idorsia holds its Annual General Meeting of Shareholders All Board proposals approved by the shareholders Allschwil, Switzerland – June 13...

New data with daridorexant to be presented at SLEEP 2024

New data with daridorexant to be presented at SLEEP 2024 Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new...

New data with daridorexant to be presented at SLEEP 2024

New data with daridorexant to be presented at SLEEP 2024 Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new...

Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024

Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 Allschwil, Switzerland –...

Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024

Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 Allschwil, Switzerland –...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Idorsia Ltd (0RQE)

Empower your portfolio: Real-time discussions and actionable trading ideas.

0RQE News

Idorsia announces financial results for the first half 2024

Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call

Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension

Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds

Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds

Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category

Idorsia holds its Annual General Meeting of Shareholders

New data with daridorexant to be presented at SLEEP 2024

New data with daridorexant to be presented at SLEEP 2024

Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024

Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024

Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders

Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders

Idorsia announces changes to Idorsia Executive Committee and Board of Directors

Idorsia announces changes to Idorsia Executive Committee and Board of Directors

0RQE Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Idorsia Ltd (0RQE) News

Idorsia Ltd (0RQE)

Empower your portfolio: Real-time discussions and actionable trading ideas.

0RQE News

Idorsia announces financial results for the first half 2024

Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call

Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension

Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds

Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds

Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category

Idorsia holds its Annual General Meeting of Shareholders

New data with daridorexant to be presented at SLEEP 2024

New data with daridorexant to be presented at SLEEP 2024

Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024

Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024

Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders

Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders

Idorsia announces changes to Idorsia Executive Committee and Board of Directors

Idorsia announces changes to Idorsia Executive Committee and Board of Directors

0RQE Discussion

Your Recent History